A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method

A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method

Abstract Background A key challenge in phase I trials is maintaining rapid escalation in order to avoid exposing too many patients to sub-therapeutic doses, while preserving safety by limiting the frequency of toxic events. Traditional rule-based designs require temporarily stopping recruitment whil...

Full description

Bibliographic Details
Main Authors: Bernard North, Hemant Mahendrakumar Kocher, Peter Sasieni
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Cancer
Subjects:
Adaptive design
Bayesian adaptive
Simulation
3 + 3 design
Maximal tolerated dose
Dose-finding
Online Access:http://link.springer.com/article/10.1186/s12885-019-5801-3

Internet

http://link.springer.com/article/10.1186/s12885-019-5801-3

Similar Items